{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:59:29Z","timestamp":1790175569036,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0380"],"award-info":[{"award-number":["W81XWH-21-1-0380"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CRI13662"],"award-info":[{"award-number":["CRI13662"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma (GBM) is a highly aggressive and lethal form of brain tumor that resists immunotherapy. Here we show that neuropeptide galanin (GAL) drives immunosuppression and immunotherapy resistance in GBM. Mechanistically, GBM cell-secreted GAL interacts with its receptor GALR3 on monocytic myeloid-derived suppressor cells (mMDSCs), triggering USP51-mediated deubiquitination of estrogen receptor-\u03b1, thereby engaging membrane-bound\n                    <jats:italic>O<\/jats:italic>\n                    -acyltransferase domain-containing 1 signaling. This signaling cascade, in turn, promotes the infiltration of immunosuppressive mMDSCs and confers ferroptosis resistance to them in the tumor microenvironment. Targeting mMDSCs through GALR3 inhibition and ferroptosis induction impairs tumor progression and activates antitumor immunity in GBM mouse models. Remarkably, combining this approach with anti-PD1 therapy achieves durable and complete tumor regression in approximately 60% of tumor-bearing mice. Our study elucidates the molecular mechanism underlying GBM immunosuppression and highlights a promising therapeutic strategy to enhance GBM response to immunotherapy.\n                  <\/jats:p>","DOI":"10.1038\/s43018-026-01221-3","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:03:18Z","timestamp":1787648598000},"page":"1387-1405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells"],"prefix":"10.1038","volume":"7","author":[{"given":"Lizhi","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6585-0145","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-7638","authenticated-orcid":false,"given":"Heba","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-5686","authenticated-orcid":false,"given":"Hardik","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1198-4776","authenticated-orcid":false,"given":"Barbara","family":"Kofler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-9992","authenticated-orcid":false,"given":"Craig M.","family":"Horbinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-9328","authenticated-orcid":false,"given":"Peiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","volume":"27","author":"PY Wen","year":"2025","unstructured":"Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 27, 2751\u20132788 (2025).","journal-title":"Neuro Oncol."},{"key":"1221_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"1221_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","volume":"187","author":"R Mathur","year":"2024","unstructured":"Mathur, R. et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell 187, 446\u2013463 (2024).","journal-title":"Cell"},{"key":"1221_CR4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312277120","volume":"120","author":"A Pant","year":"2023","unstructured":"Pant, A. & Lim, M. Overcoming EGFR inhibitor resistance in glioblastoma by targeting co-amplified genes. Proc. Natl Acad. Sci. USA 120, e2312277120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1221_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116342","volume":"44","author":"H Ali","year":"2025","unstructured":"Ali, H. et al. Neuropeptide adrenomedullin remodels stemness and macrophage dynamics in glioblastoma. Cell Rep. 44, 116342 (2025).","journal-title":"Cell Rep."},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41590-023-01605-y","volume":"24","author":"L Pang","year":"2023","unstructured":"Pang, L. et al. Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma. Nat. Immunol. 24, 1654\u20131670 (2023).","journal-title":"Nat. Immunol."},{"key":"1221_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101238","volume":"4","author":"L Pang","year":"2023","unstructured":"Pang, L. et al. Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma. Cell Rep. Med. 4, 101238 (2023).","journal-title":"Cell Rep. Med."},{"key":"1221_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI199056","volume":"136","author":"F Zhou","year":"2026","unstructured":"Zhou, F., Pang, L., Liu, Y., Khan, F. & Chen, P. Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models. J. Clin. Invest. 136, e199056 (2026).","journal-title":"J. Clin. Invest."},{"key":"1221_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1221_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/neuonc\/nox208","volume":"20","author":"A Omuro","year":"2018","unstructured":"Omuro, A. et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 20, 674\u2013686 (2018).","journal-title":"Neuro Oncol."},{"key":"1221_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol."},{"key":"1221_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Zhou, F., Ali, H., Lathia, J. D. & Chen, P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol. Immunol. 21, 1354\u20131375 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1221_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41590-022-01215-0","volume":"23","author":"AT Yeo","year":"2022","unstructured":"Yeo, A. T. et al. Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression. Nat. Immunol. 23, 971\u2013984 (2022).","journal-title":"Nat. Immunol."},{"key":"1221_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.trecan.2022.04.010","volume":"8","author":"L Pang","year":"2022","unstructured":"Pang, L., Khan, F., Heimberger, A. B. & Chen, P. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer 8, 839\u2013854 (2022).","journal-title":"Trends Cancer"},{"key":"1221_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2024.09.014","volume":"43","author":"WL Hwang","year":"2025","unstructured":"Hwang, W. L. et al. Integrating priorities at the intersection of cancer and neuroscience. Cancer Cell 43, 1\u20135 (2025).","journal-title":"Cancer Cell"},{"key":"1221_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/cmi.2017.159","volume":"15","author":"M Yao","year":"2018","unstructured":"Yao, M. et al. Cellular origin of glioblastoma and its implication in precision therapy. Cell Mol. Immunol. 15, 737\u2013739 (2018).","journal-title":"Cell Mol. Immunol."},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41556-024-01425-8","volume":"26","author":"T Nakamura","year":"2024","unstructured":"Nakamura, T. & Conrad, M. Exploiting ferroptosis vulnerabilities in cancer. Nat. Cell Biol. 26, 1407\u20131419 (2024).","journal-title":"Nat. Cell Biol."},{"key":"1221_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei, G., Zhuang, L. & Gan, B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell 42, 513\u2013534 (2024).","journal-title":"Cancer Cell"},{"key":"1221_CR20","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.cell.2023.05.003","volume":"186","author":"D Liang","year":"2023","unstructured":"Liang, D. et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 186, 2748\u20132764 (2023).","journal-title":"Cell"},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.immuni.2024.03.019","volume":"57","author":"HN Bell","year":"2024","unstructured":"Bell, H. N., Stockwell, B. R. & Zou, W. Ironing out the role of ferroptosis in immunity. Immunity 57, 941\u2013956 (2024).","journal-title":"Immunity"},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","volume":"612","author":"R Kim","year":"2022","unstructured":"Kim, R. et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature 612, 338\u2013346 (2022).","journal-title":"Nature"},{"key":"1221_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.187684","volume":"10","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Glycoprotein NMB mediates bidirectional GSC-TAM interactions to promote tumor progression. JCI Insight 10, e187684 (2025).","journal-title":"JCI Insight"},{"key":"1221_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"1221_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","volume":"35","author":"P Chen","year":"2019","unstructured":"Chen, P. et al. Symbiotic macrophage\u2013glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell 35, 868\u2013884.e6 (2019).","journal-title":"Cancer Cell"},{"key":"1221_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s43018-023-00566-3","volume":"4","author":"V Wischnewski","year":"2023","unstructured":"Wischnewski, V. et al. Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation. Nat. Cancer 4, 908\u2013924 (2023).","journal-title":"Nat. Cancer"},{"key":"1221_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah, N. et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat. Commun. 13, 767 (2022).","journal-title":"Nat. Commun."},{"key":"1221_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914236","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y. et al. Single-cell transcriptomics revealed subtype-specific tumor immune microenvironments in human glioblastomas. Front. Immunol. 13, 914236 (2022).","journal-title":"Front. Immunol."},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1158\/2159-8290.CD-19-0400","volume":"10","author":"P Chen","year":"2020","unstructured":"Chen, P. et al. Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment. Cancer Discov. 10, 371\u2013381 (2020).","journal-title":"Cancer Discov."},{"key":"1221_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","volume":"6","author":"G Wang","year":"2016","unstructured":"Wang, G. et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6, 80\u201395 (2016).","journal-title":"Cancer Discov."},{"key":"1221_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1124\/pr.112.006536","volume":"67","author":"R Lang","year":"2015","unstructured":"Lang, R. et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol. Rev. 67, 118\u2013175 (2015).","journal-title":"Pharmacol. Rev."},{"key":"1221_CR32","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/CAD.0000000000000271","volume":"26","author":"F Garner","year":"2015","unstructured":"Garner, F., Shomali, M., Paquin, D., Lyttle, C. R. & Hattersley, G. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs 26, 948\u2013956 (2015).","journal-title":"Anticancer Drugs"},{"key":"1221_CR33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.molcel.2019.06.040","volume":"75","author":"D Li","year":"2019","unstructured":"Li, D. et al. Estrogen-related hormones induce apoptosis by stabilizing Schlafen-12 protein turnover. Mol. Cell 75, 1103\u20131116 (2019).","journal-title":"Mol. Cell"},{"key":"1221_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01613-9","volume":"9","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Lipid peroxidation in osteoarthritis: focusing on 4-hydroxynonenal, malondialdehyde, and ferroptosis. Cell Death Discov. 9, 320 (2023).","journal-title":"Cell Death Discov."},{"key":"1221_CR35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ccell.2023.05.001","volume":"41","author":"JK Minami","year":"2023","unstructured":"Minami, J. K. et al. CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis. Cancer Cell 41, 1048\u20131060 (2023).","journal-title":"Cancer Cell"},{"key":"1221_CR36","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2024.01.030","volume":"187","author":"B Qiu","year":"2024","unstructured":"Qiu, B. et al. Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis. Cell 187, 1177\u20131190.e18 (2024).","journal-title":"Cell"},{"key":"1221_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266\u2013282 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1221_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01606-1","volume":"8","author":"S Sun","year":"2023","unstructured":"Sun, S., Shen, J., Jiang, J., Wang, F. & Min, J. Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduct. Target. Ther. 8, 372 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1221_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon, S. J. & Olzmann, J. A. The cell biology of ferroptosis. Nat. Rev. Mol. Cell Biol. 25, 424\u2013442 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1221_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"1221_CR41","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde, S., Leader, A. M. & Merad, M. MDSC: markers, development, states, and unaddressed complexity. Immunity 54, 875\u2013884 (2021).","journal-title":"Immunity"},{"key":"1221_CR42","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/0008-5472.CAN-19-2843","volume":"80","author":"C Porta","year":"2020","unstructured":"Porta, C. et al. Tumor-derived prostaglandin E2 promotes p50 NF-\u03baB-dependent differentiation of monocytic MDSCs. Cancer Res. 80, 2874\u20132888 (2020).","journal-title":"Cancer Res."},{"key":"1221_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993444","volume":"13","author":"GP Takacs","year":"2022","unstructured":"Takacs, G. P. et al. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+\/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner. Front. Immunol. 13, 993444 (2022).","journal-title":"Front. Immunol."},{"key":"1221_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01191","volume":"11","author":"TJ Alban","year":"2020","unstructured":"Alban, T. J. et al. Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression. Front. Immunol. 11, 1191 (2020).","journal-title":"Front. Immunol."},{"key":"1221_CR45","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro, C. et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin. Cancer Res. 22, 3924\u20133936 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1221_CR46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","volume":"163","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. METTL3 inhibits antitumor immunity by targeting m6A\u2013BHLHE41\u2013CXCL1\/CXCR2 axis to promote colorectal cancer. Gastroenterology 163, 891\u2013907 (2022).","journal-title":"Gastroenterology"},{"key":"1221_CR47","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","volume":"26","author":"S Greene","year":"2020","unstructured":"Greene, S. et al. Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-Cell immunotherapy in head and neck cancer models. Clin. Cancer Res. 26, 1420\u20131431 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1221_CR48","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.celrep.2019.07.068","volume":"28","author":"D Di Mitri","year":"2019","unstructured":"Di Mitri, D. et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 28, 2156\u20132168 (2019).","journal-title":"Cell Rep."},{"key":"1221_CR49","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/2326-6066.CIR-21-0559","volume":"10","author":"W Xuan","year":"2022","unstructured":"Xuan, W. et al. Circadian regulator CLOCK drives immunosuppression in glioblastoma. Cancer Immunol. Res. 10, 770\u2013784 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1221_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1471-4159.2011.07176.x","volume":"117","author":"M Ifuku","year":"2011","unstructured":"Ifuku, M. et al. Functional importance of inositol-1,4,5-triphosphate-induced intracellular Ca2+ mobilization in galanin-induced microglial migration. J. Neurochem. 117, 61\u201370 (2011).","journal-title":"J. Neurochem."},{"key":"1221_CR51","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/cells11050839","volume":"11","author":"D Fonseca-Rodrigues","year":"2022","unstructured":"Fonseca-Rodrigues, D., Almeida, A. & Pinto-Ribeiro, F. A new Gal in town: a systematic review of the role of galanin and its receptors in experimental pain. Cells 11, 839 (2022).","journal-title":"Cells"},{"key":"1221_CR52","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1158\/1078-0432.CCR-12-1780","volume":"18","author":"L Stevenson","year":"2012","unstructured":"Stevenson, L. et al. Identification of galanin and its receptor GALR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin. Cancer Res. 18, 5412\u20135426 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1221_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/cas.12315","volume":"105","author":"T Uehara","year":"2014","unstructured":"Uehara, T. et al. Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Sci. 105, 72\u201380 (2014).","journal-title":"Cancer Sci."},{"key":"1221_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106675","volume":"188","author":"JT Ortega","year":"2023","unstructured":"Ortega, J. T., Parmar, T. & Jastrzebska, B. Galanin receptor 3\u2014a new pharmacological target in retina degeneration. Pharmacol. Res. 188, 106675 (2023).","journal-title":"Pharmacol. Res."},{"key":"1221_CR55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-16-0502","volume":"7","author":"N Svoronos","year":"2017","unstructured":"Svoronos, N. et al. Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov. 7, 72\u201385 (2017).","journal-title":"Cancer Discov."},{"key":"1221_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43704-7","volume":"9","author":"A Koller","year":"2019","unstructured":"Koller, A. et al. Galanin is a potent modulator of cytokine and chemokine expression in human macrophages. Sci. Rep. 9, 7237 (2019).","journal-title":"Sci. Rep."},{"key":"1221_CR57","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/15548627.2018.1520549","volume":"15","author":"J Xiang","year":"2019","unstructured":"Xiang, J. et al. How does estrogen work on autophagy? Autophagy 15, 197\u2013211 (2019).","journal-title":"Autophagy"},{"key":"1221_CR58","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.4049\/jimmunol.1501785","volume":"196","author":"DW Beury","year":"2016","unstructured":"Beury, D. W. et al. Myeloid-derived suppressor cell survival and function are regulated by the transcription factor Nrf2. J. Immunol. 196, 3470\u20133478 (2016).","journal-title":"J. Immunol."},{"key":"1221_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47096-9","volume":"15","author":"S Daneshmandi","year":"2024","unstructured":"Daneshmandi, S. et al. Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies. Nat. Commun. 15, 2803 (2024).","journal-title":"Nat. Commun."},{"key":"1221_CR60","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cmet.2021.05.016","volume":"33","author":"E Dierge","year":"2021","unstructured":"Dierge, E. et al. Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects. Cell Metab. 33, 1701\u20131715 (2021).","journal-title":"Cell Metab."},{"key":"1221_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36630-w","volume":"14","author":"PS Upadhyayula","year":"2023","unstructured":"Upadhyayula, P. S. et al. Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism. Nat. Commun. 14, 1187 (2023).","journal-title":"Nat. Commun."},{"key":"1221_CR62","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-19-1355","volume":"10","author":"D Bayik","year":"2020","unstructured":"Bayik, D. et al. Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner. Cancer Discov. 10, 1210\u20131225 (2020).","journal-title":"Cancer Discov."},{"key":"1221_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn6758","volume":"15","author":"S Ghosh","year":"2023","unstructured":"Ghosh, S. et al. Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. Sci. Transl. Med. 15, eabn6758 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1221_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186034","volume":"135","author":"L Pang","year":"2025","unstructured":"Pang, L. et al. Targeting legumain-mediated cell\u2013cell interaction sensitizes glioblastoma to immunotherapy in preclinical models. J. Clin. Invest. 135, e186034 (2025).","journal-title":"J. Clin. Invest."},{"key":"1221_CR65","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1194\/jlr.D700041-JLR200","volume":"49","author":"V Matyash","year":"2008","unstructured":"Matyash, V., Liebisch, G., Kurzchalia, T. V., Shevchenko, A. & Schwudke, D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 49, 1137\u20131146 (2008).","journal-title":"J. Lipid Res."},{"key":"1221_CR66","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643\u20131660 (2020).","journal-title":"Cell"},{"key":"1221_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178628","volume":"134","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. J. Clin. Invest. 134, e178628 (2024).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01221-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01221-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01221-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:02:04Z","timestamp":1790172124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01221-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":67,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01221-3","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}